靶向广泛 B 细胞恶性肿瘤患者的异体 CD20xCD22 双靶点 CAR 的临床前证据 Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies. PubMed 2023/07/05 发表Cancer Immunol ResQ1 · IF 7.9(JCR 2025) 靶点:CD19靶点:CD20靶点:CD22技术:CAR-T非霍奇金淋巴瘤地区:美国地区:欧洲